CDXS
Codexis, Inc. NASDAQ$2.51
Pre-mkt
$2.55
+1.59%
Mkt Cap $228.1M
52w Low $0.96
53.3% of range
52w High $3.87
50d MA $1.83
200d MA $2.07
P/E (TTM)
-5.3x
EV/EBITDA
-5.5x
P/B
4.6x
Debt/Equity
1.4x
ROE
-87.0%
P/FCF
-6.0x
RSI (14)
—
ATR (14)
—
Beta
2.08
50d MA
$1.83
200d MA
$2.07
Avg Volume
2.4M
About
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEv…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11, 2026 | AMC | 0.01 | 0.11 | +1000.0% | 1.27 | +52.0% | +34.6% | +26.8% | +18.1% | +15.7% | +15.7% | — |
| Nov 6, 2025 | AMC | -0.15 | -0.22 | -46.7% | 2.04 | -19.6% | -17.2% | -14.2% | -11.8% | -5.4% | -20.1% | — |
| Aug 13, 2025 | AMC | -0.17 | -0.16 | +5.9% | 3.05 | +11.5% | +1.6% | -1.3% | -1.6% | -5.9% | -7.5% | — |
| May 14, 2025 | AMC | -0.20 | -0.25 | -25.0% | 2.47 | -9.7% | +1.6% | +0.0% | -1.6% | -0.8% | -5.3% | — |
| Feb 27, 2025 | AMC | -0.04 | -0.13 | -225.0% | 3.93 | -10.9% | -22.6% | -30.3% | -31.8% | -30.5% | -30.5% | — |
| Oct 31, 2024 | AMC | -0.25 | -0.29 | -16.0% | 3.14 | +5.7% | +11.5% | +11.1% | +21.7% | +27.7% | +33.1% | — |
| Aug 8, 2024 | AMC | -0.26 | -0.32 | -23.1% | 3.15 | -2.2% | -11.1% | -10.5% | -11.1% | -10.5% | -10.8% | — |
| May 2, 2024 | AMC | -0.17 | -0.16 | +5.9% | 3.34 | +8.4% | +17.4% | +6.6% | +5.7% | +3.6% | +3.9% | — |
| Feb 28, 2024 | AMC | -0.16 | 0.02 | +112.5% | 3.72 | +5.6% | +25.0% | +23.9% | +13.2% | +1.1% | -2.2% | — |
| Nov 2, 2023 | AMC | -0.32 | -0.26 | +18.8% | 1.80 | +7.2% | +7.2% | -3.1% | -3.3% | -9.4% | -11.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.33 | $4.37 | +0.9% | +6.5% | +5.1% | +5.3% | +6.0% | +5.8% |
| Nov 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.74 | $3.80 | +1.6% | +3.7% | +5.1% | +13.6% | +15.8% | +15.8% |
| Sep 20 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.21 | $3.19 | -0.6% | -3.4% | -9.0% | -10.0% | -9.3% | -3.4% |
| Aug 29 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.91 | $2.95 | +1.4% | -0.3% | -0.7% | -2.1% | -2.7% | -3.4% |
| Aug 19 | Benchmark | Downgrade | Buy → Hold | — | $2.91 | $2.78 | -4.5% | +3.4% | +2.1% | +3.1% | -0.3% | +4.8% |
| Aug 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.15 | $3.08 | -2.2% | -11.1% | -10.5% | -11.1% | -10.5% | -10.8% |
| May 3 | Benchmark | Maintains | Buy → Buy | — | $3.34 | $3.62 | +8.4% | +17.4% | +6.6% | +5.7% | +3.6% | +3.9% |
| Feb 29 | Benchmark | Upgrade | Hold → Buy | — | $3.72 | $3.93 | +5.6% | +25.0% | +23.9% | +13.2% | +1.1% | -2.2% |
| Nov 7 | Benchmark | Downgrade | Buy → Hold | — | $1.75 | $1.69 | -3.2% | -0.3% | -6.6% | -8.3% | -4.9% | -4.9% |
| Nov 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.93 | $1.93 | +0.0% | -9.6% | -9.8% | -15.5% | -17.1% | -14.0% |
Recent Filings
8-K
Unknown — 8-K Filing
Dr. Martinborough's board reclassification is purely administrative, preserving committee continuity and avoiding disruption to governance—investors should note no material leadership changes occurred.
Apr 14
8-K
Unknown — 8-K Filing
Codexis secured a $37.8M Merck deal and has 2027 cash runway, but full-year revenue of only $70.4M suggests slow growth; investors should monitor whether partnerships can drive profitability before cash depletion.
Mar 11
Data updated apr 25, 2026 12:36am
· Source: massive.com